Cited by 714Cardiac Ischemia and ReperfusionAcute Myocardial Infarction ResearchCardiac Fibrosis and Remodeling

Cyclosporine before PCI in Patients with Acute Myocardial Infarction

Open access
Cung, Thien-Tri, Morel, Olivier, Cayla, Guillaume, Rioufol, Gilles, Garcia-Dorado, David, Angoulvant, Denis, Bonnefoy-Cudraz, Eric, Guérin, Patrice +45 more·2015·New England Journal of Medicine

Abstract

BACKGROUND: Experimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury and reduce myocardial infarct size. We aimed to test whether cyclosporine would improve clinical outcomes and prevent adverse left ventricular remodeling. METHODS: In a multicenter, double-blind, randomized trial, we assigned 970 patients with an acute anterior ST-segment elevation myocardial infarction (STEMI) who were undergoing percutaneous coronary intervention (PCI) within 12 hours after symptom onset and who had complete occlusion of the culprit coronary artery to receive a bolus injection of cyclosporine (administered intravenously at a dose of 2.5 mg per kilogram of body weight) or matching placebo before coronary recanalization. The primary outcome was a composite of death from any cause, worsening of heart failure during the initial hospitalization, rehospitalization for heart failure, or adverse left ventricular remodeling at 1 year. Adverse left ventricular remodeling was defined as an increase of 15% or more in the left ventricular end-diastolic volume. RESULTS: A total of 395 patients in the cyclosporine group and 396 in the placebo group received the assigned study drug and had data that could be evaluated for the primary outcome at 1 year. The rate of the primary outcome was 59.0% in the cyclosporine group and 58.1% in the control group (odds ratio, 1.04; 95% confidence interval [CI], 0.78 to 1.39; P=0.77). Cyclosporine did not reduce the incidence of the separate clinical components of the primary outcome or other events, including recurrent infarction, unstable angina, and stroke. No significant difference in the safety profile was observed between the two treatment groups. CONCLUSIONS: In patients with anterior STEMI who had been referred for primary PCI, intravenous cyclosporine did not result in better clinical outcomes than those with placebo and did not prevent adverse left ventricular remodeling at 1 year. (Funded by the French Ministry of Health and NeuroVive Pharmaceutical; CIRCUS ClinicalTrials.gov number, NCT01502774; EudraCT number, 2009-013713-99.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1505489

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [20]20. with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 2014; 66: 1142-74.

Cited by

Sorted by citations

Authors
Cung, T.-T., Morel, O., Cayla, G., Rioufol, G., Garcia-Dorado, D., Angoulvant, D., Bonnefoy-Cudraz, E., Guérin, P., Elbaz, M., Delarche, N., Coste, P., Vanzetto, G., Metge, M., Aupetit, J.-F., Jouve, B., Motreff, P., Tron, C., Labeque, J.-N., Steg, P. G., Cottin, Y., Range, G., Clerc, J., Claeys, M. J., Coussement, P., Prunier, F., Moulin, F., Roth, O., Belle, L., Dubois, P., Barragan, P., Gilard, M., Piot, C., Colin, P., De Poli, F., Morice, M.-C., Ider, O., Dubois-Randé, J.-L., Unterseeh, T., Le Breton, H., Béard, T., Blanchard, D., Grollier, G., Malquarti, V., Staat, P., Sudre, A., Elmer, E., Hansson, M. J., Bergerot, C., Boussaha, I., Jossan, C., Derumeaux, G., Mewton, N., & Ovize, M.
Affiliations
  • Centre Hospitalier Universitaire de Nantes (FR)
  • Hôpitaux Universitaires de Strasbourg (FR)
  • Centre Hospitalier Universitaire de Nîmes (FR)
  • Lyon 1 Université (FR)
  • Centre Hospitalier De Pau (FR)
  • Centre Hospitalier Universitaire de Bordeaux (FR)
  • Centre Hospitalier Saint-Joseph Saint-Luc (FR)
  • Centre Hospitalier Intercommunal Aix-Pertuis (FR)
  • Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
  • Hôpital Charles-Nicolle (FR)
  • CHU Dijon Bourgogne (FR)
  • Antwerp University Hospital (BE)
  • AZ Sint-Jan (BE)
  • Centre Hospitalier Universitaire d'Angers (FR)
  • Centre Hospitalier Régional et Universitaire de Nancy (FR)
  • Centre Hospitalier de Mulhouse (FR)
  • HUmani - CHU Charleroi-Chimay (BE)
  • Clinique du Millénaire (FR)
  • Hôpital Privé Jacques Cartier (FR)
  • Centre Hospitalier Universitaire de Caen Normandie (FR)
  • Lille’s Cardiology Hospital (FR)
  • Lund University (SE)
Venue
New England Journal of Medicine
Published
2015-09-10
Volume
373
Issue
11
Pages
1021-1031
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2200357463
Cited by
713
References
34
Citations by year
2026: 38 · 2025: 46 · 2024: 48 · 2023: 55 · 2022: 62 · 2021: 57 · 2020: 75 · 2019: 79 · 2018: 70 · 2017: 70 · 2016: 92 · 2015: 20
FWCI
66.66
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • HAL (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion)
Funders
  • Lunds Universitet
  • Assistance publique-Hôpitaux de Paris
  • Universitair Ziekenhuis Antwerpen
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Cardiac Ischemia and Reperfusion
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords
cyclosporine, ST-elevation myocardial infarction, percutaneous coronary intervention, left ventricular remodeling, ischemia-reperfusion injury, myocardial infarct size, heart failure, intravenous cyclosporine, primary percutaneous coronary intervention, drug safety
MeSH terms
Peptidyl-Prolyl Isomerase D, Aged, Combined Modality Therapy, Double-Blind Method, Electrocardiography, Enzyme Inhibitors, Female, Heart Failure, Humans, Injections, Intravenous, Male, Middle Aged, Mortality, Myocardial Infarction, Cyclosporine, Ventricular Remodeling, Cyclophilins, Kaplan-Meier Estimate, Percutaneous Coronary Intervention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review